These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 34562365)

  • 1. Persistent progress.
    Cell; 2021 Oct; 184(21):5293-5296. PubMed ID: 34562365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delivering the message: How a novel technology enabled the rapid development of effective vaccines.
    Shapiro L; Losick R
    Cell; 2021 Oct; 184(21):5271-5274. PubMed ID: 34562362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Could mixing COVID vaccines boost immune response?
    Ledford H
    Nature; 2021 Feb; 590(7846):375-376. PubMed ID: 33547431
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine.
    Milane L; Amiji M
    Drug Deliv Transl Res; 2021 Aug; 11(4):1309-1315. PubMed ID: 33512669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reflections on SARS-CoV-2 new strain contagiousness and its prevention with mRNA vaccines.
    García-Vigil JL; García-Alvarez JL
    Gac Med Mex; 2021; 157(3):318. PubMed ID: 34667321
    [No Abstract]   [Full Text] [Related]  

  • 6. Learning lessons from lipids to make COVID-19 vaccines.
    Cell; 2022 Apr; 185(8):1279-1282. PubMed ID: 35385689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer.
    Ehmsen S; Asmussen A; Jeppesen SS; Nilsson AC; Østerlev S; Vestergaard H; Justesen US; Johansen IS; Frederiksen H; Ditzel HJ
    Cancer Cell; 2021 Aug; 39(8):1034-1036. PubMed ID: 34348121
    [No Abstract]   [Full Text] [Related]  

  • 8. mRNA COVID-19 vaccine is well tolerated in patients with cutaneous and systemic mastocytosis with mast cell activation symptoms and anaphylaxis.
    Rama TA; Moreira A; Castells M
    J Allergy Clin Immunol; 2021 Mar; 147(3):877-878. PubMed ID: 33485650
    [No Abstract]   [Full Text] [Related]  

  • 9. A network analysis of COVID-19 mRNA vaccine patents.
    Gaviria M; Kilic B
    Nat Biotechnol; 2021 May; 39(5):546-548. PubMed ID: 33981074
    [No Abstract]   [Full Text] [Related]  

  • 10. How COVID unlocked the power of RNA vaccines.
    Dolgin E
    Nature; 2021 Jan; 589(7841):189-191. PubMed ID: 33437061
    [No Abstract]   [Full Text] [Related]  

  • 11. A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice.
    de Alwis R; Gan ES; Chen S; Leong YS; Tan HC; Zhang SL; Yau C; Low JGH; Kalimuddin S; Matsuda D; Allen EC; Hartman P; Park KJ; Alayyoubi M; Bhaskaran H; Dukanovic A; Bao Y; Clemente B; Vega J; Roberts S; Gonzalez JA; Sablad M; Yelin R; Taylor W; Tachikawa K; Parker S; Karmali P; Davis J; Sullivan BM; Sullivan SM; Hughes SG; Chivukula P; Ooi EE
    Mol Ther; 2021 Jun; 29(6):1970-1983. PubMed ID: 33823303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthetic Messenger RNA-Based Vaccines: from Scorn to Hype.
    Pascolo S
    Viruses; 2021 Feb; 13(2):. PubMed ID: 33572452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Messenger RNA vaccines against SARS-CoV-2.
    Topol EJ
    Cell; 2021 Mar; 184(6):1401. PubMed ID: 33740443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lessons From Bacille Calmette-Guérin for SARS-CoV-2 Vaccine Candidates.
    Behr MA; Divangahi M; Schurr E
    J Infect Dis; 2021 Feb; 223(2):189-191. PubMed ID: 33535239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2.
    Huang Q; Ji K; Tian S; Wang F; Huang B; Tong Z; Tan S; Hao J; Wang Q; Tan W; Gao GF; Yan J
    Nat Commun; 2021 Feb; 12(1):776. PubMed ID: 33536425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Century of mRNA Vaccines: COVID-19 Vaccines and Allergy.
    Ortega Rodríguez NR; Audícana Berasategui MT; de la Hoz Caballer B; Valero Santiago A
    J Investig Allergol Clin Immunol; 2021 Feb; 31(1):89-91. PubMed ID: 33393485
    [No Abstract]   [Full Text] [Related]  

  • 17. Neutralizing SARS-CoV-2.
    Poeschla E
    Elife; 2020 Dec; 9():. PubMed ID: 33320086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study.
    Li J; Hui A; Zhang X; Yang Y; Tang R; Ye H; Ji R; Lin M; Zhu Z; Türeci Ö; Lagkadinou E; Jia S; Pan H; Peng F; Ma Z; Wu Z; Guo X; Shi Y; Muik A; Şahin U; Zhu L; Zhu F
    Nat Med; 2021 Jun; 27(6):1062-1070. PubMed ID: 33888900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feds sign off on mixing and matching COVID-19 vaccines, but evidence gaps remain.
    Duong D
    CMAJ; 2021 Jun; 193(25):E967-E968. PubMed ID: 34155052
    [No Abstract]   [Full Text] [Related]  

  • 20. Recent advances in therapeutic modalities and vaccines to counter COVID-19/SARS-CoV-2.
    Bilal M; Iqbal HMN
    Hum Vaccin Immunother; 2020 Dec; 16(12):3034-3042. PubMed ID: 32845742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.